Quarterly report pursuant to Section 13 or 15(d)

Licensing and Other Arrangements - Novartis - NIS793 (Details)

v3.24.1.u1
Licensing and Other Arrangements - Novartis - NIS793 (Details)
$ in Thousands
3 Months Ended 12 Months Ended
Sep. 30, 2015
USD ($)
item
Mar. 31, 2024
USD ($)
Mar. 31, 2023
USD ($)
Dec. 31, 2017
USD ($)
Dec. 31, 2015
USD ($)
Dec. 31, 2023
USD ($)
Licensing and other arrangements            
Revenue from contracts with customers   $ 1,000        
Novartis International | License Agreement            
Licensing and other arrangements            
Agreement termination prior written notice period 180 days          
Number of performance obligations | item 1          
Cash payment received         $ 37,000  
Revenue from contracts with customers   0 $ 0 $ 10,000 $ 37,000  
Maximum milestone payments entitled to receive $ 480,000          
Minimum period eligible to receive royalties 10 years          
Contract assets   0       $ 0
Contract liabilities   0       0
Capitalized contract costs   $ 0       $ 0